Table 3.
Study outcomes.
| Outcome | HCTZ | Placebo | p-value |
|---|---|---|---|
| Primary | |||
| Weight change/day | − 1.78 ± 1.08 | − 1.05 ± 1.51 | 0.062 |
| Secondary | |||
| Length of stay (days) | 9 ± 8 | 8 ± 9 | 0.37 |
| Change in creatinine (mg/dL) | 0.50 ± 0.37 | 0.27 ± 0.40 | 0.05 |
| Need for vasoactive drugs (%) | 19.2 | 12.0 | 0.70 |
| Congestion score | − 5.4 ± 4.6 | − 4.8 ± 4.6 | 0.68 |
| Change in dyspnea scale | − 4.7 ± 2.7 | − 3.2 ± 3.6 | 0.14 |
| Thirst scale | − 1.7 ± 4.5 | 0.5 ± 3.8 | 0.21 |
| Change in natriuretic peptides (%)a | − 11.1 ± 100.3 | − 33.3 ± 50.9 | 0.83 |
| Safety | |||
| In-hospital mortality (%, [n]) | 3.8 (1) | 0 (0) | 1.00 |
| Hypernatremia (%) | 0 | 4.8 | 0.47 |
| Hypokalemia (%) | 3.8 | 4.5 | 1 |
| Hyperkalemia (%) | 0 | 0 | 1 |
| Increase in creatinine > 0.3 mg/dL (%) | 58 | 41 | 0.38 |
| Ventricular arrhythmias (%) | 3.8 | 4 | 1.00 |
| Hemodialysis (%) | 3.8 | 0 | 1.00 |
Plus–minus values are means ± standard deviation.
aNatriuretic peptides were collected in all patients at baseline and 55% of study populations had a 3-day or discharge follow-up sample collected, with no difference between groups.